Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. 1999

C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

OBJECTIVE To assess the efficacy of salvage therapy containing ritonavir and saquinavir after failure of indinavir- or nelfinavir-containing regimens, and to determine correlates of success or failure. METHODS Retrospective chart review. SETTING. The Moore Clinic - the HIV clinic of Johns Hopkins Hospital. METHODS Forty-one HIV-infected patients were identified through physician contacts, referrals from other providers, and review of a comprehensive clinical database. METHODS To determine response to salvage therapy, HIV-1 viral RNA (absolute and log10-transformed) was measured using the Roche Amplicor quantitative HIV-1 RNA assay after initiation of the salvage regimen. Potential correlates of response included: viral RNA at the time of switch; viral RNA at the time of switch as a percentage of baseline viral RNA; magnitude of decline in viral RNA; and the interval between virologic failure of single protease inhibitor therapy and switch to the salvage regimen. RESULTS Thirteen (56.5%) of 23 patients failing indinavir responded to salvage therapy (HIV RNA < 400 copies/ml) with persistence throughout the follow-up period (median of 37 weeks; range 18-67 weeks). Mean absolute viral RNA at the time of switch was 20 238 copies/ml (median, 9281) compared with 42 953 copies/ml (median, 24 650) for the 10 non-responders. Mean log10 viral RNA at switch was 3.804 for responders versus 4.405 for non-responders (P = 0.040). Among four responders who had failed nelfinavir, mean viral RNA was 9634 copies/ml and mean log10 viral RNA was 3.749 at the time of switch. Two non-responders had a mean viral RNA of 21 551 and a mean log10 viral RNA of 4.037 at switch. CONCLUSIONS In contrast with previous reports, salvage regimens containing ritonavir and/or saquinavir can be effective and durable following the failure of combination regimens containing either indinavir or nelfinavir. Salvage therapy may be more likely to succeed when it is initiated early in failure at low viral loads.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
February 2003, European journal of medical research,
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
August 1999, AIDS (London, England),
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
January 2001, HIV clinical trials,
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
September 1999, The Annals of pharmacotherapy,
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
January 2000, The Pediatric infectious disease journal,
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
July 2003, AIDS (London, England),
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
August 2004, Journal of acquired immune deficiency syndromes (1999),
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
January 2000, MMW Fortschritte der Medizin,
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
September 2001, AIDS (London, England),
C S Hall, and C P Raines, and S H Barnett, and R D Moore, and J E Gallant
October 2002, HIV medicine,
Copied contents to your clipboard!